Stay updated on Alvocidib Biomarker AML Phase 2 Clinical Trial

Sign up to get notified when there's something new on the Alvocidib Biomarker AML Phase 2 Clinical Trial page.
Latest website image capture
Clouds background image

Latest updates to the Alvocidib Biomarker AML Phase 2 Clinical Trial page

  1. Check
    5 days ago
    Change Detected
    Summary
    The Alvocidib Phase 2 AML study record is displayed, including its termination due to slow enrollment, treatment arms, eligibility criteria, study locations, and outcome information. The record also includes study history and links to its protocol and statistical analysis plan.
    Difference
    71%
    Check dated 2026-11-07T13:55:46.000Z thumbnail image
  2. Check
    12 days ago
    Change Detected
    Summary
    The footer revision label changes from v3.7.2 to v3.8.0 while the study record remains unavailable.
    Difference
    0.2%
    Check dated 2026-10-31T14:34:45.000Z thumbnail image
  3. Check
    19 days ago
    Change Detected
    Summary
    A site-wide NIH banner announces a transition in terminology from “Artificial Intelligence” to “Super Intelligence” and links to updates and FAQs.
    Difference
    1%
    Check dated 2026-10-24T17:56:47.000Z thumbnail image
  4. Check
    26 days ago
    Change Detected
    Summary
    The footer’s site revision marker changed from v3.7.1 to v3.7.2 while the page continued to display a 403 error.
    Difference
    0.2%
    Check dated 2026-10-17T20:09:41.000Z thumbnail image
  5. Check
    33 days ago
    Change Detected
    Summary
    The footer revision identifier changes from v3.7.0 to v3.7.1 on the 403 page.
    Difference
    0.2%
    Check dated 2026-10-10T20:36:16.000Z thumbnail image
  6. Check
    54 days ago
    Change Detected
    Summary
    The page now shows a new Revision: v3.7.0 label, and a number of study document entries were removed from the Study Documents section.
    Difference
    19%
    Check dated 2026-09-19T20:22:56.000Z thumbnail image

Stay in the know with updates to Alvocidib Biomarker AML Phase 2 Clinical Trial

Enter your email address, and we'll notify you when there's something new on the Alvocidib Biomarker AML Phase 2 Clinical Trial page.